Американское общество гирудотерапии

Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia

Research article published in Journal of stroke and cerebrovascular diseases (2024)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportРазработка лекарственных препаратовSukumaran M et al. · Journal of stroke and cerebrovascular diseases, 2024

Abstract

OBJECTIVES: Heparin-induced thrombocytopenia is a known complication of heparin exposure with potentially life-threatening sequelae. Direct thrombin inhibitors can be substituted for heparin in patients with heparin-induced thrombocytopenia that require anticoagulation. However, the use of direct thrombin inhibitors as a substitute for heparin has not been widely reported in the neuroendovascular literature. MATERIALS AND METHODS: Here we report the first use of the direct thrombin inhibitor bivalirudin in a neuroendovascular procedure as a substitute for heparin in a patient with a ruptured pseudoaneurysm and heparin-induced thrombocytopenia, and review the literature on the use of bivalirudin and argatroban for such patients. RESULTS: Bivalirudin was safely and effectively used in the case reported, with no thrombotic or hemorrhagic complications. Our literature review revealed a paucity of studies on the use of heparin alternatives, including bivalirudin, in neuroendovascular procedures in patients with heparin-induced thrombocytopenia. CONCLUSIONS: Heparin-induced thrombocytopenia is an important iatrogenic disease process in patients undergoing neuroendovascular procedures, and developing protocols to diagnose and manage heparin-induced thrombocytopenia is important for healthcare systems. While further research needs to be done to establish the full range of anticoagulation options to substitute for heparin, our case indicates bivalirudin as a potential candidate.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase ReportsReview
Indexed MeSH termsHumansMaleMiddle AgedAneurysm, FalseAneurysm, RupturedAnticoagulantsAntithrombinsDrug SubstitutionEndovascular ProceduresHeparinHirudinsIntracranial Aneurysm

Резюме

Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia.

Почему это важно для гирудотерапии

This article presents a case of bivalirudin use as a heparin substitute during neuroendovascular treatment of a ruptured pseudoaneurysm in a patient with heparin-induced thrombocytopenia, accompanied by a literature review of direct thrombin inhibitors (bivalirudin and argatroban) in neuroendovascular settings. The reported case had no thrombotic or hemorrhagic complications, and the authors note a paucity of evidence in this niche. For ASH, no defensible leech or hirudotherapy connection exists from the abstract: it does not mention leeches, hirudin, or leech-derived therapy. Honest caveat: this is largely a single case report plus review, involves no actual leeches or hirudotherapy, and makes no efficacy claims beyond the described case.

Цитирование

Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia

Sukumaran M et al. · Journal of stroke and cerebrovascular diseases, 2024

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.